MediWound Announces the Appointment of Hani Luxenburg as Chief Financial Officer By Investing.com


© Eran Lavie, MediWound PR MediWound (MDWD) Announces the Appointment of Hani Luxenburg as Chief Financial Officer

MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company specializing in next-generation biotherapeutic solutions for tissue repair and regeneration, is pleased to announce the appointment of Ms. Hani Luxenburg as its new Chief Financial Officer, effective May 14, 2023. Ms. Luxenburg will replace Mr. Boaz Gur-Lavie, who has served as MediWound’s Chief Financial Officer for the past four years. Mr. Gur-Lavie will remain with the Company through July 31, 2023 to ensure an orderly transition.

With over 20 years of progressive leadership experience managing financial and accounting operations, Ms. Luxenburg joins MediWound with a proven track record delivering positive business growth and profitable financial results in the technology and life sciences sectors. Most recently, Ms. Luxenburg served as Chief Financial Officer at BIRD Aerosystems. Prior to that, she held senior finance roles at AstraZeneca, Alvarion Technologies Ltd., and Ernst & Young. Ms. Luxenburg holds a Bachelor of Law from the Interdisciplinary Center (IDC) Herzilya, Israel and a Bachelor of Arts in Economics and Accounting from the University of Haifa, Israel. In addition, she is a certified public accountant and a member of the Israel Bar Association.

“We are thrilled to welcome Hani to our team. Her extensive experience and financial acumen will be instrumental in helping us achieve our strategic goals and drive long-term value for our shareholders. We sincerely appreciate Boaz’s financial, business development and commercial leadership that enabled us to transform MediWound. We thank him for his valuable contributions during his tenure and wish him continued success in his future endeavors,” said Ofer Gonen, CEO of MediWound.

Ms. Luxenburg added, “I am honored to join the dynamic leadership team at MediWound at this pivotal stage in the Company’s development. In addition to the day-to-day financial operations, I look forward to working as part of the team to support the U.S. launch of NexoBrid planned in the very near-term and the promising development opportunities presented by EscharEx. MediWound is poised for meaningful growth, and I am eager to help realize its potential as a global biopharmaceutical company.”

Mr. Gur-Lavie said, “It has been a privilege to work alongside such a talented team for the past four years. The strategic, commercial, and financial actions initiated over that time period have greatly improved the Company’s balance sheet and established a solid foundation for future growth and profitability. I would like to thank Ofer for his leadership. I enjoyed working with him and believe MediWound is well positioned to achieve its goals. I look forward to assisting Hani in the transition and watching the Company’s continued success.

Original Source Link